NCT02071927View on ClinicalTrials.gov

Study of the Glutaminase Inhibitor CB-839 in Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

October 31, 2016

Study Completion Date

December 31, 2016

Conditions
Acute Myeloid Leukemia (AML)Acute Lymphocytic Leukemia (ALL)
Interventions
DRUG

CB-839

Single-agent CB-839

DRUG

CB-Aza

CB-839 in combination with standard dose azacitidine

Trial Locations (5)

14263

Roswell Park Cancer Institute, Buffalo

37203

Tennessee Oncology, PLLC, Nashville

60611

Northwestern University Feinberg School of Medicine, Chicago

77030

University of Texas MD Anderson Cancer Center, Houston

80218

Colorado Blood Cancer Institute, Denver

Sponsors
All Listed Sponsors
lead

Calithera Biosciences, Inc

INDUSTRY